Castle Biosciences surges 67% after InvestingPro Fair Value call

Castle Biosciences, a molecular diagnostics firm focusing on cancer detection, witnessed an astonishing 67% increase in its stock price over a three-month period following a May 2026 assessment by InvestingPro, which deemed the company undervalued. This illustrates the value of utilizing Fair Value analysis to pinpoint potential investment prospects.

When Castle Biosciences was trading at $18.63 on May 12, 2026, the company's intrinsic value was estimated at $28.20 by InvestingPro's Fair Value models, indicating a potential gain of 51%. Despite generating $339.92 million in revenue, the company had a negative EBITDA of -$18.35 million and a market capitalization of $1.04 billion at the time.

The stock had been volatile in the months preceding this surge, dropping by 13.9% in May alone, presenting an opportune entry point identified through Fair Value analysis. Following the initial identification at $18.63, Castle Biosciences reached $34.20 by early August 2026, resulting in a 67% total return that surpassed the original Fair Value prediction.

The stock initially hit its target price of $31.15 before continuing to rise. Several factors contributed to the Fair Value thesis. Castle Biosciences surpassed Q2 2026 earnings expectations, leading to an uptick in share price as revenue climbed to $357.28 million and EBITDA improved to -$16.52 million. The company achieved significant accomplishments such as receiving New York approval for its atopic dermatitis test and reaching 100,000 orders for its Barrett’s esophagus test.

BTIG increased its price target based on robust revenue performance, while the melanoma test exhibited superior performance compared to other risk assessment tools. InvestingPro's Fair Value methodology combines several valuation techniques, such as discounted cash flow models, comparisons with similar companies, and analyst consensus targets, to determine intrinsic worth.

By taking margin of safety into account and projecting future cash flows, Fair Value offers investors a comprehensive understanding of whether a stock is trading above or below its true value. This success story of Castle Biosciences highlights the potential of systematic Fair Value analysis in locating mispriced investment opportunities.

Subscribers to InvestingPro have access to real-time Fair Value calculations for thousands of stocks, along with detailed financial health scores and AI-driven insights. Discover current undervalued opportunities using InvestingPro before the market adopts the analysis.